Application of a small molecule inhibitor screen approach to identify CXCR4 downstream signaling pathways that promote a mesenchymal and fulvestrant‑resistant phenotype in breast cancer cells

Matossian,Margarite D.; Elliott,Steven; Rhodes,Lyndsay V.; Martin,Elizabeth  C.; Hoang,Van T.; Burks,Hope E.; Zuercher,William J.; Drewry,David  H.; Collins‑Burow,Bridgette M.; Burow,Matthew E.

doi:10.3892/ol.2021.12641

Application of a small molecule inhibitor screen approach to identify CXCR4 downstream signaling pathways that promote a mesenchymal and fulvestrant‑resistant phenotype in breast cancer cells

Authors:
- Margarite D. Matossian
- Steven Elliott
- Lyndsay V. Rhodes
- Elizabeth C. Martin
- Van T. Hoang
- Hope E. Burks
- William J. Zuercher
- David H. Drewry
- Bridgette M. Collins‑Burow
- Matthew E. Burow
View Affiliations

Affiliations: Department of Medicine, Section of Hematology and Oncology, Tulane University School of Medicine, New Orleans, LA 70112, USA, Department of Biology, Florida Gulf Coast University, Fort Myers, FL 33965, USA, Department of Biological and Agricultural Engineering Biology, Louisiana State University, Baton Rouge, LA 70803, USA, Structural Genomics Consortium, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
Published online on: March 16, 2021 https://doi.org/10.3892/ol.2021.12641
Article Number: 380
Copyright: © Matossian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemokine receptor 4 (CXCR4) and its ligand stromal‑derived factor 1 (SDF‑1) have well‑characterized functions in cancer metastasis; however, the specific mechanisms through which CXCR4 promotes a metastatic and drug‑resistant phenotype remain widely unknown. The aim of the present study was to demonstrate the application of a phenotypic screening approach using a small molecule inhibitor library to identify potential CXCR4‑mediated signaling pathways. The present study demonstrated a new application of the Published Kinase Inhibitor Set (PKIS), a library of small molecule inhibitors from diverse chemotype series with varying levels of selectivity, in a phenotypic medium‑throughput screen to identify potential mechanisms to pursue. Crystal violet staining and brightfield microscopy were employed to evaluate relative cell survival and changes to cell morphology in the screens. ‘Hits’ or lead active compounds in the first screen were PKIS inhibitors that reversed mesenchymal morphologies in CXCR4‑activated breast cancer cells without the COOH‑terminal domain (MCF‑7‑CXCR4‑ΔCTD) and in the phenotypically mesenchymal triple‑negative breast cancer cells (MDA‑MB‑231, BT‑549 and MDA‑MB‑157), used as positive controls. In a following screen, the phenotypic and cell viability screen was used with a positive control that was both morphologically mesenchymal and had acquired fulvestrant resistance. Compounds within the same chemotype series were identified that exhibited biological activity in the screens, the ‘active’ inhibitors, were compared with inactive compounds. Relative kinase activity was obtained using published datasets to discover candidate kinase targets responsible for CXCR4 activity. MAP4K4 and MINK reversed both the mesenchymal and drug‑resistant phenotypes, NEK9 and DYRK2 only reversed the mesenchymal morphology, and kinases, including ROS, LCK, HCK and LTK, altered the fulvestrant‑resistant phenotype. Oligoarray experiments revealed pathways affected in CXCR4‑activated cells, and these pathways were compared with the present screening approach to validate our screening tool. The oligoarray approach identified the integrin‑mediated, ephrin B‑related, RhoA, RAC1 and ErbB signaling pathways to be upregulated in MCF‑7‑CXCR4‑ΔCTD cells, with ephrin B signaling also identified in the PKIS phenotypic screen. The present screening tool may be used to discover potential mechanisms of targeted signaling pathways in solid cancers.

View Figures

View References

1	Eggert US: The why and how of phenotypic small-molecule screens. Nat Chem Biol. 9:206–209. 2013. View Article : Google Scholar : PubMed/NCBI
2	Elkins JM, Fedele V, Szklarz M, Abdul Azeez KR, Salah E, Mikolajczyk J, Romanov S, Sepetov N, Huang XP, Roth BL, et al: Comprehensive characterization of the published kinase inhibitor set. Nat Biotechnol. 34:95–103. 2016. View Article : Google Scholar : PubMed/NCBI
3	Drewry DH, Wells CI, Andrews DM, Angell R, Al-Ali H, Axtman AD, Capuzzi SJ, Elkins JM, Ettmayer P, Frederiksen M, et al: Progress towards a public chemogenomic set for protein kinases and a call for contributions. PLoS One. 12:e01815852017. View Article : Google Scholar : PubMed/NCBI
4	Matossian MD, Elliott S, Hoang VT, Burks HE, Phamduy TB, Chrisey DB, Zuercher WJ, Drewry DH, Wells C, Collins-Burrow B and Burrow ME: Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes. PLoS One. 12:e01778022017. View Article : Google Scholar : PubMed/NCBI
5	Rubin JB: Chemokine signaling in cancer: One hump or two? Semin Cancer Biol. 19:116–122. 2009. View Article : Google Scholar : PubMed/NCBI
6	Balkwill FR: The chemokine system and cancer. J Pathol. 226:148–157. 2012. View Article : Google Scholar : PubMed/NCBI
7	Chatterjee S, Behnam Azad B and Nimmagadda S: The intricate role of CXCR4 in cancer. Adv Cancer Res. 124:31–82. 2014. View Article : Google Scholar : PubMed/NCBI
8	Bendall LJ, Baraz R, Juarez J, Shen W and Bradstock KF: Defective p38 mitogen-activated protein kinase signaling impairs chemotaxic but not proliferative responses to stromal-derived factor-1alpha in acute lymphoblastic leukemia. Cancer Res. 65:3290–3298. 2005. View Article : Google Scholar : PubMed/NCBI
9	Grande F, Giancotti G, Ioele G, Occhiuzzi MA and Garofalo A: An update on small molecules targeting CXCR4 as starting points for the development of anti-cancer therapeutics. Eur J Med Chem. 139:519–530. 2017. View Article : Google Scholar : PubMed/NCBI
10	Walenkamp AME, Lapa C, Herrmann K and Wester HJ: CXCR4 Ligands: The next big hit? J Nuc Med. 58 (Suppl 2):77S–82S. 2017. View Article : Google Scholar
11	Xu C, Zhao H, Chen H and Yao Q: CXCR4 in breast cancer: Oncogenic role and therapeutic targeting. Drug Des Devel Ther. 9:4953–4964. 2015.PubMed/NCBI
12	Eckert F, Schilbach K, Klumpp L, Bardoscia L, Sezgin EC, Schwab M, Zips D and Huber SM: Potential role of CXCR4 targeting in the context of radiotherapy and immunotherapy of cancer. Front Immunol. 9:30182018. View Article : Google Scholar : PubMed/NCBI
13	Mukherjee D and Zhao J: The role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res. 3:46–57. 2013.PubMed/NCBI
14	Salvucci O, Bouchard A, Baccarelli A, Deschênes J, Sauter G, Simon R, Bianchi R and Basik M: The role of CXCR4 receptor expression in breast cancer: A large tissue microarray study. Breast Cancer Res Treat. 97:275–283. 2006. View Article : Google Scholar : PubMed/NCBI
15	Zhang Z, Ni C, Chen W, Wu P, Wang Z, Yin J, Huang J and Qiu F: Expression of CXCR4 and breast cancer prognosis: A systematic review and meta-analysis. BMC Cancer. 14:492014. View Article : Google Scholar : PubMed/NCBI
16	Okuyama Kishima M, de Oliveira CE, Banin-Hirata BK, Losi-Guembarovski R, Brajão de Oliveira K, Amarante MK and Watanabe MA: Immunohistochemical expression of CXCR4 on breast cancer and its clinical significance. Anal Cell Pathol (Amst). 2015:8910202015.PubMed/NCBI
17	Chu QD, Panu L, Holm NT, Li BD, Johnson LW and Zhang S: High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome. J Surg Res. 159:689–695. 2010. View Article : Google Scholar : PubMed/NCBI
18	Hassan S, Ferrario C, Saragovi U, Quenneville L, Gaboury L, Baccarelli A, Salvucci O and Basik M: The influence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer. Am J Pathol. 175:66–73. 2009. View Article : Google Scholar : PubMed/NCBI
19	Krohn A, Song YH, Muehlberg F, Dross L, Bechmann C and Alt E: CXCR4 receptor positive spheroid forming cells are responsible for tumor invasion in vitro. Cancer Lett. 280:65–71. 2009. View Article : Google Scholar : PubMed/NCBI
20	Graham NA and Graeber TG: Complexity of metastasis-associated SDF-1 ligand signaling in breast cancer stem cells. Proc Natl Acad Sci USA. 111:7503–7504. 2014. View Article : Google Scholar : PubMed/NCBI
21	Yi T, Zhai B, Yu Y, Kiyotsugu Y, Raschle T, Etzkorn M, Seo HC, Nagiec M, Luna RE, Reinherz EL, et al: Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci USA. 111:E2182–E2190. 2014. View Article : Google Scholar : PubMed/NCBI
22	Mego M, Cholujova D, Minarik G, Sedlackova T, Gronesova P, Karaba M, Benca J, Cingelova S, Cierna Z, Manasova D, et al: CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer. BMC Cancer. 16:1272016. View Article : Google Scholar : PubMed/NCBI
23	Brabletz T, Kalluri R, Nieto MA and Weinberg RA: EMT in cancer. Nat Rev Cancer. 18:128–134. 2018. View Article : Google Scholar : PubMed/NCBI
24	Felipe Lima J, Nofech-Mozes S, Bayani J and Bartlett JM: EMT in breast carcinoma-A review. J Clin Med. 5:652016. View Article : Google Scholar
25	Leggett SE, Sim JY, Rubins JE, Neronha ZJ, Williams EK and Wong IY: Morphological single cell profiling of the epithelial-mesenchymal transition. Integr Biol (Camb). 8:1133–1144. 2016. View Article : Google Scholar : PubMed/NCBI
26	Nelson CM, Khauv D, Bissell MJ and Radisky DC: Change in cell shape is required for matrix metalloproteinase-induced epithelial-mesenchymal transition of mammary epithelial cells. J Cell Biochem. 105:25–33. 2008. View Article : Google Scholar : PubMed/NCBI
27	Ueda Y, Neel NF, Schutyser E, Raman D and Richmond A: Deletion of the COOH-terminal domain of CXC chemokine receptor 4 leads to the down-regulation of cell-to-cell contact, enhanced motility and proliferation in breast carcinoma cells. Cancer Res. 66:5665–5675. 2006. View Article : Google Scholar : PubMed/NCBI
28	Sobolik T, Su YJ, Wells S, Ayers GD, Cook RS and Richmond A: CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways. Mol Biol Cell. 25:566–582. 2014. View Article : Google Scholar : PubMed/NCBI
29	Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
30	Rhodes LR, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, et al: Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 71:603–613. 2010. View Article : Google Scholar : PubMed/NCBI
31	Liang S, Peng X, Li X, Yang P, Xie L, Li Y, Du C and Zhang F: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin. Oncotarget. 6:1020–1030. 2015. View Article : Google Scholar : PubMed/NCBI
32	Wang Y, Yan L, Zhang L, Xu H, Chen T, Li Y, Wang H, Chen S, Wang W, Chen C and Yang Q: NT21MP negatively regulates paclitaxel-resistant cells by targeting miR-155-3p and miR-155-5p via the CXCR4 pathway in breast cancer. Int J Oncol. 53:1043–1054. 2018.PubMed/NCBI
33	Liu S, Xie SM, Yang-Kolodji G and Tripathy D: Targeting the tumor microenviroment by CXCR4 inhibition to abrogate trastuzumab resistance in HER2-positive breast cancer. Cancer Res. 79 (Suppl 4):P5-03-04. 2019.
34	Rhodes LV, Antoon JW, Muir SE, Elliott S, Beckman BS and Burrow ME: Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. Mol Cancer. 9:2952010. View Article : Google Scholar : PubMed/NCBI
35	Rhodes LV, Bratton MR, Zhu Y, Tilghman SL, Muir SE, Salvo VA, Tate CR, Elliott S, Nephew KP, Collins-Burow BM and Burow ME: Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells. Exp Cell Res. 317:2573–2581. 2011. View Article : Google Scholar : PubMed/NCBI
36	Sauvé K, Lepage J, Sanchez M, Heveker N and Tremblay A: Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Cancer Res. 69:5793–5800. 2009. View Article : Google Scholar : PubMed/NCBI
37	Dubrovska A, Hartung A, Bouchez LC, Walker JR, Reddy VA, Cho CY and Schultz PG: CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. British J Cancer. 107:43–52. 2012. View Article : Google Scholar
38	Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, et al: Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 66:11954–11966. 2006. View Article : Google Scholar : PubMed/NCBI
39	Ptasznik A, Urbanowska E, Chinta S, Costa MA, Katz BA, Stanislaus MA, Demir G, Linnekin D, Pan ZK and Gewirtz AM: Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. J Exp Med. 196:667–678. 2002. View Article : Google Scholar : PubMed/NCBI
40	Dillmann F, Veldwijk MR, Laufs S, Sperandio M, Calandra G, Wenz F, Zeller J and Fruehauf S: Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib. Leuk Lymphoma. 50:1676–1686. 2009. View Article : Google Scholar : PubMed/NCBI
41	Smith-Pearson PS, Greuber EK, Yogalingam G and Pendergast AM: Abl kinases are required for invadopodia formation and chemokine-induced invasion. J Biol Chem. 285:40201–40211. 2010. View Article : Google Scholar : PubMed/NCBI
42	Kaenel P, Mosimann M and Andres AC: The multifaceted roles of Eph/ephrin signaling in breast cancer. Cell Adh Migr. 6:138–147. 2012. View Article : Google Scholar : PubMed/NCBI
43	Haldimann M, Custer D, Munarini N, Stirnimann C, Zürcher G, Rohrbach V, Djonov V, Ziemiecki A and Andres AC: Deregulated ephrin-B2 expression in the mammary gland interferes with the development of both the glandular epithelium and vasculature and promotes metastasis formation. Int J Oncol. 35:525–536. 2009.PubMed/NCBI
44	Lamb CA, Helguero LA, Fabris V, Lucas C, Molinolo AA and Lanari C: Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma. Breast Cancer Res Treat. 79:25–35. 2003. View Article : Google Scholar : PubMed/NCBI
45	Giuliano M, Schiff R, Osborne CK and Trivedi MV: Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast. 20 (Suppl 3):S42–S49. 2011. View Article : Google Scholar : PubMed/NCBI